All News

Article

SLE Conference Preview: progress in biologics

Md Yuzaiful Md Yusof, MRCP(UK), PhD Oct 26, 2025

The pharmacology treatment including biologics, cellular-based therapies, and Bi-specific T-cell Engager (BiTE) in systemic lupus erythematosus (SLE) is a rapidly expanding field of research that provides excitement and optimism to both the patients and the physicians.

Come to our first #HealthLiteracy poster of #ACR25! #0190 Cluster analysis >900 people with IA Lowest health literacy cluster assoc w: 4× ⬆️anxiety/depression 2× ⬆️disease activity, vs highest HL Higher HL assoc w older age & ⬆️comorbidities but fewer mental health Sx @RheumNow https://t.co/iIRXaOl4qZ

How does cMRI change over time in cardiac EGPA? Cheng et al. retrospectively reviewed: - 11 EGPA pt with LGE on initial cMRI Despite treatment: - 10/11 persistent LGE on 2nd cMRI - 4/4 on 3rd - 2/2 on 4th Unclear use as a monitor of tx response @RheumNow #ACR25

#0773 Anti-MDA5 epitope mapping identifies key regions (aa 201-300, 601-700) linked to treatment resistance & poor prognosis in DM-ILD and even IIPs. Epitope-specific antibodies could refine risk stratification & guide therapy in ILD beyond autoimmune disease. @RheumNow #ACR25 https://t.co/moRffVGZPn

https://x.com/DrMiniDey/status/1982464233108546038/photo/1

#ACR25 Abstr#0772. Should we be worried of #SLE patients with low uPCR 0.25-0.49? Kidney biopsy in N=28 + poor prognostic (Non-White, active serology or active sediment) - 71% had LN (No class IV or Mixed) - 46% actionable LN Cost-effectiveness data needed. #ACRBest @RheumNow https://t.co/Bt3fuA3aJh

Organ Specific Recommendations-ACR guidelines for Management of SLE by Dr Lisa Sammaritano. @RheumNow #ACR2025 https://t.co/ilKWG8CQbe

https://x.com/NaziburM/status/1982463066194276479/photo/1

AI-enhanced MRI integrating STIR and T1-weighted MRI with BME data reflecting both inflammatory and structural changes, enabling the AI model to predict clinical diagnoses of axSpA with accuracy of 82%. Successfully identified axSpA patients who did not meet the ASAS criteria for https://t.co/dLlGj0ZFpj

https://x.com/synovialjoints/status/1982462228751409477/photo/1

Join us at 5pm CST for Day 1 #ACR25 recap! https://t.co/EwZSiPhysF

Plenary session at #ACR25! #0772 When should we biopsy in SLE? In pts with uPCR 0.25-0.49 g/g + LN predictors, 69% already had LN (many Class III/V). Low C3/C4 were most important factors. 0.5 g/g cutoff may delay diagnosis and treatment. Time to rethink thresholds? @RheumNow

#LLM can be #virtual #tutor for 👇 #OSCE RCT - better competence &confidence #AI & #medical #education AI trained to #tutor Also grading OSCE #AI + human @RheumNow @ACRheum #26S17 https://t.co/CzKoxyjpY8

https://x.com/Janetbirdope/status/1982460602929860822/photo/1

Early, low level proteinuria is a harbinger in SLE. ~50% with elevated UPCR but <0.5 had actionable LN on early bx. Risk factor = low c3/c4 Urine biomarkers promising #ACRBest #ACR25 @RheumNow https://t.co/WuNPKeqeid

#Pros and #cons of #AI Need to know both Need to assess AI #quality and #accuracy ‘Assume AI WILL be used’ JHausmann By trainees, patients and medical personnel Train #faculty re #AI #ACR25 @RheumNow @ACRheum #26S17 https://t.co/CvPDQPbueW

https://x.com/Janetbirdope/status/1982459379963121877/photo/1

What's new in the Pre-RA world? Slowly unraveling mechanisms and biology associated to transition from CCP+ asymptomatic pre-RA state to clinical RA Here is my summary of a few abstracts presented at #ACR25 proposing biomarkers beyond the realm of clinical and classical

From Dr. Petri at Plenary - even small amounts of proteinuria are a PROBLEM. Reduction of microalbuminuria by even 10% improves mortality! #ACR25 @RheumNow https://t.co/hjmH26vXIb

https://x.com/Dr_Brian_MD/status/1982458294351397093/photo/1

#AI for medical use is fast moving governance is Impt Protect Privacy Facilitate trainees to LEARN Involve #IT, ethicists, users ‘We will enter a world where all we do medically is recorded’ J Hausmann said #ACR25 @RheumNow @ACRheum #26S17 https://t.co/zWjy4u99Yo

https://x.com/Janetbirdope/status/1982458065438863806/photo/1

Topical therapies in cutaneous lupus - find the right level Victoria Werth #ACR25 SLE guideline session @RheumNow https://t.co/o3gBuFkr4n

#Medical #learners more optimistic re #AI than gen pop’n! Tips stress privacy - pt info in AI goes to private company All trainees will use #AI Set boundaries - change eval where can’t use AI only AI listening notes 👇 #cognitive #deskilling #ACR25 @RheumNow @ACRheum 26S17 https://t.co/UzajaimOcG

https://x.com/Janetbirdope/status/1982456877033156899/photo/1

For #SLE pleuropericarditis: recommendation intentionally tries to leverage use of colchicine/NSAIDs vs. GCs But there are special situations where GCs are req’d: > Concomitant active SLE > CI to NSAIDs/Col > Recurrent pericarditis > Late pregnancy > 💊interxns #ACR25 @RheumNow https://t.co/sLL72t3Qhf

HIGH YIELD🚨Summary of Organ Specific Recommendations-ACR guidelines for Management of SLE by Dr Lisa Sammaritano. @RheumNow #ACR2025 https://t.co/ysSTKOz1ym

https://x.com/MartinezZayasMd/status/1982452209938747850/photo/1

Year in Review: Regency Trial showed that LN pts given obinutuzumab achieved CRR at 76 wks (46.4%) vs. PBO. Take note: the Regency trial did not evaluate the extrarenal effects of Obinutuzumab in #SLE, thats for a diff study. #ACR25 @RheumNow https://t.co/WJssU1DbzZ

https://x.com/RHEUMarampa/status/1982445925025853468/photo/1

Topics

All News

SLE Conference Preview: progress in biologics

Do you get our email newsletter?